Views on Emerging Issues Pertaining to Data Monitoring Committees for Adaptive Trials

Therapeutic Innovation and Regulatory Science

Volumn 47, Issue 4, 2013, Pages 495-502

  Antonijevic, Zoran ^a   Gallo, Paul ^b   Chuang Stein, Christy ^c   Dragalin, Vladimir ^d   Loewy, John ^e   Menon, Sandeep ^c,f   Miller, Eva R ^g   Morgan, Caroline Claire ^a   Sanchez, Matilde ^h  

^a Cytel Incorporated   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PFIZER INC   (United States)

^d ICON PLC   (United Kingdom)

^e Biostatistics qPharmetra Inc   (United States)

^f BOSTON UNIVERSITY   (United States)

^g Quality Data Services Inc   (United States)

^h ARENA PHARMACEUTICALS   (United States)

Author keywords

adaptive trials; communication; data monitoring committees; membership; roles and responsibilities

Indexed keywords

ALGORITHM; ARTICLE; CLINICAL TRIAL (TOPIC); COMPENSATION; CONFIDENTIALITY; CONFLICT; DECISION MAKING; EXPECTATION; HUMAN; INFORMATION PROCESSING; INTERPERSONAL COMMUNICATION; KNOWLEDGE; MONITORING; NON PROFIT ORGANIZATION; PATIENT SAFETY; PLANNING; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSIBILITY; STUDY DESIGN; TRAINING; WORK EXPERIENCE; WORKSHOP;

EID: 84879519364     PISSN: 21684790     EISSN: 21649200     Source Type: Journal    
DOI: 10.1177/2168479013486996     Document Type: Article

References (13)

1. European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007. http://www.emea.europa.eu/pdfs/human/ewp/245902enadopted.pdf. Accessed October 18, 2007.
2. US Food and Drug Administration. Draft guidance for industry: adaptive design clinical trials for drugs and biologics. February 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf.
3. Ellenberg S,Fleming T,DeMets DData Monitoring Committees in Clinical Trials: A Practical Perspective. New York, NY: Wiley; 2002:.
4. US Food and Drug Administration. Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees. March 2006. http://www.fda.gov/downloads/Regulatoryinformation/Guidances/ucm127073.pdf.
5. European Medicines Agency. Guideline on data monitoring committees. 2006.July 27, 2005. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf.
6. Wang SJ,Hung JHM,O'Neill R.Adaptive design clinical trials and trial logistics models in CNS drug development.Eur Neuropsychopharmacol. 2011;21:159-166.
7. Shen J,Preskorn S,Dragalin V, et al.How adaptive trial designs can increase efficiency in psychiatric drug development: a case study.Innov Clin Neurosci. 2011;8 (26): 26-34.
8. Gallo P,Fardipour P,Dragalin V,Littman GS,Bretz F.Data monitoring in adaptive dose-ranging trials.Stat Biopharm Res. 2010;2 (4): 513-521.
9. Chow SC,Corey R,Lin M.On the independence of data monitoring committee in adaptive design clinical trials.J Biopharm Stat. 2012;22 (4): 853-867.
10. Gallo P.Confidentiality and trial integrity issues for adaptive designs.Drug Inf J. 2006;40:445-450.
11. Califf RM,Harrington RA,Blazing MA.Premature release of data from clinical trials of ezetimibe.N Engl J Med. 2009;361 (7): 712-717.
12. Barker AD,Sigman CC,Kelloff GJ,Hylton NM,Berry DA,Esserman LJ.I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.Clin Pharmacol Ther. 2009;86:97-100.
13. Gaydos B,Anderson K,Berry DA, et al.Good practices for adaptive clinical trials in pharmaceutical product development.Drug Inf J. 2009;43 (5): 539-565.